Students are increasingly interested in focusing on digital technology, information technology, artificial intelligence, and cybersecurity in their career and technical education courses, according to ...
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s REC-4881 has shown “strong and durable” efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback